Abstract P4-08-04: PD-L1 expression and prognosis in triple negative breast cancer (TNBC): An analysis of 265 patients (pts) treated with standard therapy for stage I-III disease
MV Dieci(University of Padua), PierFranco Conte(University of Padua), Serena Bonaguro(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), Enrico Cumerlato(University of Padua), CA Giorgi(University of Padua), Enrico Orvieto(AULSS 2 Marca Trevigiana), Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua)
Cited by 2
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830